Feature | July 17, 2012| Dave Fornell

An Introduction to Atherectomy Systems

The Bayer-Medrad Navitus atherectomy catheter has two cutting surfaces and integrated aspiration.

Atherectomy devices are used in the cath lab to debulk lesions by cutting or laser ablating plaque, calcium and tissue hyperplasia from vessel walls, allowing recanalization of the vessel lumen as an end in itself, or in preparation for stenting. While some devices have an indication for the coronaries, the primary use of these devices is for peripheral artery disease (PAD) in the legs. 

Healthcare providers are increasingly viewing PAD as a progressive, chronic disease that requires a continuum of treatment, where few patients are treated only once.  Many are treated to restore flow whenever the disease re-occludes a vessel, or a new vessel develops a blockage.  The goal is to improve quality of life and prevent amputation. 

Treatments that restore bloodflow without reducing the ability to treat the vessel in the future are better suited for PAD.  Atherectomy is seen by many as an ideal therapy for PAD because it can restore flow while removing the plaque burden and does not leave behind a permanent obstacle to future treatments, such as a stent. Stenting in the legs leads to frequent restenosis or fractured stent struts, and can be problematic or prevent repeat interventional or open surgical repairs.

Cost of treatment is always a concern for both reimbursement and institutions. Atherectomy may be a less costly approach to PAD over the life of a patient than open surgery or ballooning and stenting.  Within the atherectomy market, the vendors must demonstrate both economic advantages and procedural success. The total cost (including the number) of devices needed for a procedure, the duration of lumen patency and reduction of side effects that require additional treatments influence use of these technologies.

Cardiovascular Systems Inc. (CSI) recently shared 12-month data from the COMPLIANCE 360° study of severely calcified above-the-knee lesions. The prospective study of 50 patients (with 65 lesions) at nine U.S. sites randomized patients equally to balloon angioplasty alone versus the Diamondback Orbital Atherectomy System with adjunctive ballooning.  The study showed that avoiding stents and reducing restenosis saved money. The approximate incremental cost savings of the atherectomy group at six months was $5,264 per additional acute adjunctive stenting or restenosis avoided.  The study also found the angioplasty arm required bailout stenting in 84 percent of the procedures to achieve results equivalent to the Diamondback arm. 

There is increasing interest in atherectomy treatments in vessels below the knee. Successfully recanalizing arteries to the ankle and foot can reduce pain, restore mobility and reverse ulceration, which may have a major impact on the costs of chronic wound care in lower extremities.

There was a setback for coronary atherectomy with the results of the ROTAXUS (A Prospective, Randomized Trial of High-Speed Rotational Atherectomy Prior to Paclitaxel-Eluting Stent Implantation in Complex Calcified Coronary Lesions) trial, presented at the 2011 Transcatheter Cardiovascular Therapeutics (TCT) symposium. The trial found the process was not superior to standard balloon angioplasty and decreased the efficacy of the stent in reducing new tissue growth within the blood vessel.

Drug-eluting stents (DES) are liberally used in complex lesions. Heavily calcified stenoses have not been adequately studied, and form a challenge for immediate and late outcomes. Rotational atherectomy has been shown to effectively modify calcified plaques and facilitate stent delivery and expansion. In patients with complex calcified lesions, rotablation followed by DES seems a rational combination, but there was a lack of evidence prior to the ROTAXUS trial. 

 

Comparing Scanners 

This article served as an introduction to an atherectomy system comparison chart in the July-August 2012 print issue of DAIC. The chart can be accessed in the comparison chart tab at the top of the screen, or at www.dicardiology.com/comparison-charts?t=Atherectomy+Systems  The chart included the following vendors: 

 

Bayer HealthCare (Medrad) - www.interventional.bayer.com

Boston Scientific - www.bostonscientific.com

Covidien - www.turbohawkdevice.com

Cardiovascular Systems Inc. (CSI) - www.csi360.com

Spectranetics - www.spectranetics.com

Related Content

First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Arterial Disease (PAD)| July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Edwards Sapien 3 TAVR valve will be implanted in asymptomatic aortic stenosis patients in the EARLY TAVR Trial
Feature | Heart Valve Technology| July 14, 2017
July 14, 2017 — Morristown Medical Center, part of Atlantic Health System, has randomized the first patient in the wo
long-duration dual anti-platelet therapy (L-DAPT) compared to short-duration dual antiplatelet (S-DAPT) after DES stent implantation
News | Antiplatelet and Anticoagulation Therapies| July 12, 2017
June 12, 2017 — Researchers have evaluated the long-term efficacy and safety of long-duration dual anti-platelet ther
Medtronic's CoreValve Evolut R gained FDA approval for intermediate risk patients

An illustration of the self-expanding CoreValve Evolut R TAVR valve half deployed in the aortic root.

Feature | Heart Valve Technology| July 10, 2017
The U.S. Food and Drug Administration (FDA) has cleared an additional indication to expand the use Medtronic's self-...
Patient Race, Gender Both Important in Predicting Heart Attack Symptoms in the ER
News | Cath Lab| July 07, 2017
Researchers at the George Washington University (GW) found that certain symptoms are more and less predictive of...
ACCESS PTS Study Demonstrates Efficacy of EKOS Therapy for Post-Thrombotic Syndrome
News | Deep Vein Thrombosis| July 07, 2017
BTG plc recently highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th...
Heartflow FFR-CT can noninvasively assess the hemodynamic impact of coronary lesions to avoid the need for an invasive angiogram.

HeartFlow FFR-CT can noninvasively assess the hemodynamic impact of coronary lesions to avoid the need for an invasive angiogram.

Technology | CT Angiography (CTA)| July 06, 2017
July 6, 2017 — GE Healthcare and HeartFlow Inc.
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD)| June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Edwards Sapien 3 cleared by FDA to use for valve in valve mitral procedures

One of the top stories for the month was the Edwards Sapien 3 TAVR valve gaining FDA clearance for use in transcatheter valve-in-valve aortic and mitral procedures. 

Feature | June 30, 2017
June 30, 2017 — Here is the list of the most popular pieces of content on the Diagnostic and Interventional Cardiolog
Overlay Init